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Summary 
Major histocompatibility complex class II-associated invariant chain (Ii) provides several important 
functions that regulate class II expression and function. One of these is the ability to inhibit 
class II peptide loading early in biosynthesis. This allows for efficient class II folding and egress 
from the endoplasmic reticulum, and protects the class II peptide binding site from loading with 
peptides before entry into endosomal compartments. The ability of Ii to interact with class II 
and interfere with peptide loading has been mapped to Ii exon 3, which encodes amino acids 
82-107. This same region of Ii has been described as a nested set of class II-associated Ii peptides 
(CLIPs) that are transiently associated with class II in normal cells and accumulate in human 
histocompatibility leukocyte antigen-DM-negative cell lines. Currently it is not clear how CLIP 
and the CLIP region of Ii blocks peptide binding. CLIP may bind directly to the class II peptide 
binding site, or may bind elsewhere on class II and modulate class II peptide binding a11osterically. 
In this report, we show that CLIP can interact with many different murine and human class 
II molecules, but that the affinity of this interaction is controlled by polymorphic residues in 
the class II chains.  Likewise, structural changes in CLIP also modulate class II binding in an 
allele-dependent manner. Finally, the specificity and kinetics of CLIP binding to class II molecule 
is similar to antigenic peptide binding to class II. These data indicate that CLIP binds to class 
II in an analogous fashion as conventional antigenic peptides, suggesting that the CLIP segment 
of Ii may actually occupy the class II peptide binding site. 
I 
n recent years it has become clear that invariant chain (Ii) 1 
plays a central role in the functional expression of MHC 
class II molecules. Ii has been shown to regulate class II as- 
sembly, endosomal localization, association with antigenic 
peptide, cell surface expression, and functional interaction with 
CD4-positive T  cells (1). This is dramatically illustrated in 
the analysis of mice lacking Ii expression (2-4), where the 
level of class II expression is reduced and there are significant 
defects in the generation and function of the CD4-positive 
population of T  cells.  One interesting feature of Ii is that 
different functions can often be associated with distinct seg- 
ments of the Ii protein. For example, endosomal localization 
can be attributed to sequences in the cytosolic and transmem- 
brane domains (5-10), class II association is mediated by amino 
acids 80-104 encoded by exon 3 in Ii (11-13), antigen presen- 
tation can be selectively enhanced by the p41 form of Ii (9, 
1  Abbreviations used in this paper: CLIP, class II-associated  invariant  chain 
peptide; EK, endoplasmic  reticulum; Ii, invariant chain. 
14), and T cell interaction can be mediated by the chondroitin 
sulfate form of Ii (15). 
One segment of Ii that has been the focus of much recent 
attention is the class II-associated Ii peptide (CLIP) region. 
CLIP was first identified by sequence analysis of peptides eluted 
from  class  II  (16). Interestingly,  in  normal  cells,  CLIP 
represents only a small component of the peptide associated 
with class II (16-18),  whereas in B cells that lack expression 
of HLA-DM (19, 20) or carry structural defects in class II 
(21), CLIP can occupy >50% of the class II molecules (22, 
23).  Although these results do not exclude the possibility 
that CLIP may simply be the predominant peptide available 
for class II loading in HLA-DM-negative B cells, recent studies 
(24)  suggest that class II associated  with CLIP is an inter- 
mediate in the normal processing and dissociation of Ii from 
class II. Interestingly, CLIP is encoded by exon 3 of Ii, the 
same region that is required for class II-Ii association (11-13). 
Taken together, these results suggest that the CLIP region 
of Ii forms an intimate and essential interaction with class 
II that persists  into endosomal compartments. During pro- 
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CLIP region results in the transient  association of class  II 
with CLIP peptide in normal cells and the persistence of the 
class II-CLIP complex in HLA-DM defective cell lines. 
One important function ofli is the ability to interfere with 
class II peptide binding (25, 26). This can have profound effects 
on both the ability of Ii to modulate presentation of endoge- 
nous antigens (27, 28) and the ability of Ii to facilitate class 
II folding and transport from the endoplasmic reticulum (ER) 
to the Golgi apparatus (29-32).  Interestingly, the ability of 
Ii to interfere with class II peptide loading has also been mapped 
to the CLIP segment (13).  Thus,  the CLIP segment of Ii 
is essential both for Ii association with class  II and for the 
chaperone functions of Ii in the EtL. 
Although it is not clear where CLIP binds to class II, one 
possibility is that CLIP actually binds  the class  II peptide 
binding site. This possibility was originally raised when CLIP 
was first isolated from class II and shown to interfere with 
class II binding to antigenic peptides (16). In this modal, CLIP 
would function by acting as a surrogate peptide for class II 
in the ER, possibly providing similar functions for class  II 
as peptide binding in the EK does for class I (33). Alterna- 
tively, CLIP may bind outside of the peptide binding groove 
and  modulate  class  II  peptide binding  allosterically.  This 
possibility is supported by the inability of CLIP to generate 
SDS-stable class II dimers (34) (although this may be allele- 
dependent [17,  35],  and some structural constraints on as- 
sembly of CLIP into  the class  II peptide binding  groove 
(discussed in 1,  18).  In this report,  we show that CLIP as- 
sociation with class II is regulated by allelic polymorphism 
and is remarkably similar in biochemical parameters to class 
II association with known antigenic peptide.  These results 
support the possibility that CLIP interacts with class II within 
the peptide binding groove. 
Materials and Methods 
Cell Lines and MHC Purification.  The following EBV-trans- 
formed homozygous cell lines  were used as sources  of human 
HLA class II molecules  06):  LG2 (DRBI*0101  [DR1]);  MAT 
(DILBI*0301 [DR3]); PREISS (DRBI*0401  [DK4w4]); BIN40 
(DKBI*0404  [DR.4w14]);  SWEIG (DRBl*11011  [DR5]);  and 
PITOUT  (DRBI*0701  [DK7]).  In  some instances,  transfected 
fibroblasts were used: L416.3 (DRBS*0101 [DR2w2a]); TR81.19 
(DRB3*0101 [DK52a]); and L257.6 (DILB4*0101 [DRw53]). For 
mouse class II molecules, the following cell lines were used: A20 
(I-A  d, I-E a) (37); CH12 (I-A  k, I-E  k) (37); LS102.9 (I-A  s) (38); and 
DB27.4 (I-A  b) (39). 
MHC molecules were purified essentiaUy as described previously 
(40). Briefly, human class II molecules were purified by affinity chro- 
matography using the LB3.1 (36) monoclonal antibody. Mouse class 
II molecules were purified by the use of the MKD6 [I-A  a (37)]; 
10.3.6 [I-A k (37)]; 14.44 [I-E  a and I-E  k (37)]; and Y3JP [I-A  s and 
I-A  b (38)] monodonal antibodies. 
MHC Peptide Binding Assays.  Purified mouse or human class 
II  molecules  (5-500  nM)  were  incubated with  5-25 nM  nsI- 
radiolabeled peptides for 48 h in PBS containing 5% DMSO in 
the presence of a protease inhibitor mixture. Purified peptides were 
iodinated using the chloramine-T method (41). The final concen- 
trations of protease inhibitors were:  1 mM PMSF, 1.3 mM 1.10 
phenanthroline, 73/zM pepstatin A, 8 mM EDTA, 6 mM N-ethyl- 
maleimide, and 200 #M Ncc-p-tosyl-t-lysine chloromethyl ketone. 
Final detergent concentration in the incubation mixture was 2.6% 
digitonin (I-A  a and I-A  k) or 0.05% NP-40 (all other class II mol- 
ecules). Class II-peptide complexes were separated from flee pep- 
tide by gel filtration on Sephadex G-50  (Pharmacia,  Piscataway, 
NJ) or TSK2000 (TOSOHAAS, MontgomeryviUe,  PA) columns, 
and the fraction of peptide bound was calculated as previously de- 
scribed (42). In preliminary experiments, each of the DR prepara- 
tions was titered in the presence of fixed amounts of radiolabeled 
peptides to determine the concentration of class II molecules neces- 
sary to bind 10-20% of the total radioactivity. All subsequent inhibi- 
tion and direct binding assays were then performed using this 
class II concentration. In the inhibition assays, inhibitory peptides 
were typically tested at concentrations ranging from 120/~g/ml 
to 1.2 ng/ml. The data were then plotted, and the dose yielding 
50% inhibition was measured. Each peptide was tested in two to 
four independent experiments. 
Peptide Synthesis.  Peptides were synthesized  as previously de- 
scribed (43). Peptides were purified  to  >95%  homogeneity by 
reverse-phase HPLC. The purity of these synthetic peptides was 
assayed on an analytical reverse-phase column and their composi- 
tion ascertained by amino acid analysis, sequencing, and/or mass 
spectrometry analysis. 
Association and Dissociation Rates, and Scatckard Analysis.  To mea- 
sure association rates, 20-60 nM purified DR1 was incubated with 
40,000 cpm (5-25 nM) of either radiolabeled 12sI YHA307-319 or 
11~ human Ii 80-103  (M --* L analogue) in the presence of pro- 
tease inhibitor cocktail and determined as described in the previous 
section. Percent bound radioactivity was measured by gel filtration 
after the indicated  incubation times. 
To measure disssociation rates, large amounts of preformed com- 
plexes were prepared  by incubating radiolabeled  peptides  with 
purified class II molecules for 2 d at room temperature.  The condi- 
tions employed in this step were identical  to those employed in 
the analytic direct binding assays, except the class II concentration 
was usually two- to threefold higher and radiolabeled peptide con- 
centration 10-fold higher. After 2 d, peptide-class II complexes were 
isolated by gel filtration and incubated at room temperature in the 
presence of at least a 1,000-fold excess of unlabeled peptide  (30 
/zg/ml) and protease inhibitors for varying amounts of time. The 
percent  of peptide still bound to class II was then measured by 
repeating the gel filtration step at the indicated  times. 
Scatchard analysis  was performed by incubating, in the conditions 
described above, ,,o100 nM of purified DR1 for 2 d at room tem- 
perature in the presence of 5-25 nM radiolabeled 12sI YHA307-319 
or 12sI human Ii 80-103 (M -* L analogue) and varying amounts 
of unlabeled  HA 307-319  or human Ii 80-103. 
Results and Discussion 
Affinity of Class II-CLIP Interactions Is Determined by AI- 
lelic Polymorphism in Class II.  To examine the ability of CLiP 
to interact with various class  II molecules, synthetic CLIP 
peptides of both mouse (Ii 85-101)  and human (Ii 80-103) 
origin were assayed for their ability to compete for binding 
of radiolabeled antigenic peptides. The data are summarized 
in Table 1. Very little difference, if any, was detected between 
the inhibitory capacity of mouse and human CLIP. Both pep- 
tides bound to all the class II molecules tested,  indicating 
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Binding Assays Using Radiolabeled Peptide Antigens and 
Purified Class II 
ICs0 nM values 
Human Ii 
Mouse Ii  Human Ii  80--103 
85-101  80-103  (M-L analogue) 
Class II mouse 
lAb  74  32  44 
IA  d  5.3  7.5  1,760 
IA  k  13,333  16,666  >20,000 
IA  s  32  49  1,459 
IE  d  1,186  682  ND 
IE  k  304  364  ND 
Class II human 
DR1  1.2  0.89  0.63 
DR2w2a  15  31  91 
DR3  77  118  2,650 
DR4w4  49  141  1,216 
DR4w14  16  12  417 
DR5  114  441  1,333 
DR7  24  40  21 
DR52a  27,647  16,786  ND 
DRw53  13  8.2  97 
Inhibitory capacity of the mouse Ii 85-101 (sequence  KPVSQMRMA- 
TPLLMKPM), human Ii 80-103 (sequence LPKPPKPVSKMRMAT- 
PLLMGALPM), and human Ii 80-103, M --* L analogue (sequence 
YLPKPPKPVSKLRLATPLLLQALPL)  in various binding assays using 
radiolabeled peptide antigens and purified class II molecules  of mouse and 
human origins. 
that CLIP binding is remarkably degenerate in its ability to 
interact  with different class  II molecules. 
Although both mouse and human CLIP bound to all class 
II molecules tested, the relative apparent affinity of this in- 
teraction was dramatically affected by polymorphism in class 
II (Table 1). For example, the inhibitory ability of CLiP varied 
between I-A  a and  I-A  k by >1,000-fold,  and between DR1 
and DR52a by >10,000-fold.  Interestingly,  CLIP has been 
readily isolated from normal cells in the naturally processed 
form from those class II molecules that have the strongest 
inhibitory capacities, such as DR1,  I-A  a, and I-A  b (16,  17, 
44).  In contrast,  CLIP has not been detected,  or detected 
at low levels,  in peptides isolated from normal  cell class II 
molecules with lower binding affinity for CLIP, such as DR3, 
DR7, I-A k, and I-E  k (18, 45). Taken  together,  these results 
demonstrate that CLIP is promiscuous in its binding to class 
II molecules, consistent with the role of CLIP in class II folding 
and in class II-Ii association. However, the relative inhibiting 
capacity of CLIP peptides can be modulated by allelic poly- 
morphism in class II that are mostly localized in the antigen 
binding groove, consistent with  the possibility that  CLIP 
may also bind directly to the peptide binding site in class II. 
Identification of CLiP Sequences that Regulate Allele-specific 
Class II Interaction.  To measure direct binding of CLIP to 
class II, CLIP peptides were synthesized that contained an 
NH2-terminal tyrosine. In addition,  the various methionine 
residues in the CLIP sequence were changed to leucine to 
avoid oxidation during the labeling procedure. Although in 
most cases the analog CLIP peptides were able to compete 
for peptide binding at an efficiency  similar to that of wild- 
type peptides, in some cases the analogues showed a dramatic 
loss in class II binding (Table 1). The most significant effect 
was for I-A  a binding, where the human analog peptide had 
<2,000-fold binding activity, as did the wild-type peptide. 
These data indicate that for some alleles, in particular I-A  a, 
I-A  s, and DR4, one or more of the four methionine residues 
in the CLIP peptide are critical for class II association.  In 
addition, the strict allele association of the sensitivity of the 
methionine  to leucine analogues further  supports the idea 
that the ability of CLIP to interact with class II is controlled 
by polymorphic residues within class  II. 
Specificity and Kinetics of Class II Association with CLIP Are 
Indistinguishable from Class II Association with Antigenic Pep- 
tide.  To further characterize class II-CLIP interactions, the 
binding  of radiolabeled CLIP was compared with binding 
of radiolabeled antigenic  peptide  HA 307-319.  DR1  was 
chosen because it bound the wild-type and analog (radiola- 
beled) CLIP similarly,  and to avoid problems in interpreta- 
tion of the results due to contaminating products of the B3 
or B5 DR loci. When the kinetics of CLIP-DR1 and HA 
307-319-DK1 interactions were investigated, both peptides 
displayed virtually indistinguishable  on-rates. In both cases, 
the association rate appeared to follow a slow pseudo-first 
order kinetics and was nearly complete by 2-3  d  at room 
temperature (Fig.  1 A). Likewise, once formed, both com- 
plexes were remarkably stable, with half-lives of 1-3 d at 37~ 
and 3-9 d at room temperature (Fig. 1 B). Interestingly, CLIP 
association rates were moderately (threefold) faster than those 
of HA 307-319. This may reflect the recent finding that CLIP 
is more readily dissociated from class II at low pH than are 
antigen  peptides (46). 
By Scatchard  analysis,  similar  affinities  were detected in 
two independent experiments for DR1 association with CLIP 
(1.1-2.1 nM) and with HA 307-319 (1.2-3.8 riM). Most im- 
portantly,  the Scatchard analysis  allowed estimation of the 
fraction of DK1 molecules accessible to binding of the HA 
307-319 or the CLIP peptide. The figures obtained were re- 
markably similar (4.0-6.6% and 5.4-7.3% for the CLIP pep- 
tides and HA 307-319, respectively) (Fig.  2). These results 
suggest that:  (a) only a fraction of the DR1 molecules are 
receptive to binding for the HA 307-319,  presumably be- 
cause the binding grooves of the remaining molecules are oc- 
cupied by preexisting naturally processed peptides; and (b) 
the same fraction is accessible to DR1 binding for the CLIP 
peptide,  suggesting that  either  the HA peptide and CLIP 
bind in the same antigen binding groove of class II, or that 
if the binding sites are not completely overlapping, occupancy 
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Figure  1.  Kinetics  of association of HA 307-319 (O) and 
human li 80-103 (M ~  L) to purified  DR1. Association  rates 
are shown in A, and the inset shows an enlargement of the 
early linear part of the binding isotherms. Dissociation rates 
are shown in B. Closed and open symbols refer to DR1/HA 
307-319 and DR1/human  Ii 80-103 (M ~  L) complexes, 
respectively.  The experiments were performed both at room 
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Figure 2.  Scatchard plots  for 
DR1/HA 307-319 (closed circles) and 
DR1/human Ii 80-103 (open circles) 
interactions. 
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of the antigen binding site would preclude occupancy of the 
CLIP binding site. 
Finally, the specificity of the HA 307-319 and CLIP binding 
to DR1 was probed by the use of a panel of various peptide 
ligands with differing affinities for the DR1 antigen binding 
groove.  The same peptides were tested in parallel  for their 
capacity to inhibit DR1-HA 307-319 and DR1-CLIP inter- 
actions.  The results of this analysis are shown in Table 2. A 
striking similarity was observed between the two sets of data: 
the OVA 323 reiterative,  ML65Kd 464-487, poly A .52, and 
the HA 307-319 and CLIP peptides were very good inhibi- 
tors of  both DR1-CLIP and DR1-HA 307-319 interactions. 
Peptides TT 830-843, ROW, and TT 830-843 (831Y) were 
intermediate inhibitors in both cases, and peptides HA 307-319 
(309H), L. rep 12-26, OVA 323-336, and Lol p I 1-20 were 
very poor inhibitors of  both interactions.  In conclusion, these 
data illustrate the remarkable similarities in the specificity of 
the CLIP and HA 307-319 interactions with DR1, as probed 
by their capacity of being inhibited by an excess of unrelated 
peptide ligands. 
In summary, biochemical analysis of the interaction be- 
tween CLIP peptides and purified class II molecules indicates 
that this interaction is remarkably similar to class II binding 
of conventional antigenic peptides.  CLIP binding is very 
promiscuous, yet MHC polymorphism can dramatically affect 
the capacity of antigenic peptides to bind class II. CLIP binding 
to DR1 displays the slow off-on rates characteristic of pep- 
tide binding in the antigen binding groove.  Scatchard  anal- 
ysis suggests that the same fraction of sites is accessible for 
binding to CLIP and the antigenic peptide HA 307-319,  and 
the specificity of the two interactions, in terms of their sensi- 
tivity to inhibition from unrelated ligands, is virtually indis- 
tinguishable. Although not conclusive,  these data are com- 
patible with only two explanations. According to the first 
Table  2.  Inhibitory Capacity of a Panel of Unrelated Peptides  for the DR1/'2sI HA 307-319 and DRIpZSI Human Ii 80-103, 
M  "-~ L  Analog Interactions 
Peptide  Sequence 
Relative inhibitory capacity for 
DR1/12sI 
DR1/12sI  Human Ii 80-103 
HA307-319  (M-L analogue) 
HA 307-319  PKYVKQNTLKLAT  1.0  1.0 
Human Ii 80-103  LPKPPKPVSKMRMATPLLMGALPM  5.6  12 
OVA 323-339 Reiterative  YYVRAVRAYLTT  5.2  4.5 
M.  leprae 65kD Y464-487  YTLLQAAPALDKLKLTGDEATGANI  6.0  10 
Poly A  .52  yAA(14)AAAKTAAAAa-NH2  17  14 
TT 830-843  QYIKANSKFIGITE  0.50  0.38 
ROW  YAHAAHAAHAAHAAHAA  0.067  0.10 
TT 830-843 analogue  QYQKANSKFIGITE  0.14  0.060 
HA 307-319 analogue  PKHVKQNTLKLAT  0.0019  0.0013 
Lambda rep.  12-26  YLEDARRLKAIYEKKK  0.0004  0.0005 
OVA 323-336  ISQAVHAAHAEINE  0.0002  0.0017 
Lol pl  1-20  IAKVPPGPNITAEYGDKWLD  0.0002  0.0002 
To avoid  discrepancies  due to differences  in sensitivity  to inhibition  of the two assays  due to differential  specific  activity  of the two labeled  compounds, 
the data are expressed in relative inhibitory  capacity. Before standardization, the ICs0% for the HA 307-319 was 5.0 and 30 nM in the 12si HA 
307-319 and 12si human Ii 80-103 assays, respectively. 
681  Sette et al. explanation,  two different binding sites exist for CLIP and 
antigenic peptides. These two binding sites are so structur- 
ally similar or strictly interdependent at the structural level 
as to be indistinguishable at the biochemical level. It should 
be noted that the crystal structure of DR1 molecules has not 
revealed any obvious peptide binding sites other than the an- 
tigen binding groove.  Thus, according to a much simpler 
and perhaps more likely alternative,  CLIP binds in the very 
same binding groove used by antigenic peptides. 
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